Commercial Metrics
Summary of commercial performance metrics for due diligence. Detailed underlying data available on request.
Headline (2025)
Revenue trajectory
Operating revenue (management view), 2020-2025 actual and 2026 target. 2025 equals the audited net revenue (cifra de negocios, €604K); earlier years include other operating income, so the base differs slightly from the statutory figure on the P&L.
Recognised revenue. Cumulative 2020-2025: €1,727K recognised (€2,045K signed).
The gap between signed contracts (€2,045K) and recognised revenue (€1,727K), ~€318K, reflects multi-year contracts that will be recognised in future periods.
Sales cycle (typical)
Retention and expansion
Retention is high, and the base expands in two distinct layers. This is the direct answer to "does the number include upsells?": on the recurring base through renewals and account growth, and in pharma through repeat programmes.
Ribera Salud / Hospital de Torrejón: long-term, multi-hospital flagship.
Visiba Care: renewed.
Boehringer Ingelheim: multiple programmes (sponsored app, GPPGA calculator, evidence webinar).
Eli Lilly: SALT and ASALT calculators.
CRO channel (ICON, Quantificare): one relationship opening multiple studies (Takeda, Sanofi, Visterra).
Gross retention on the recurring base is high; net revenue retention (NRR) is being measured, and the mechanisms above are what position the recurring base to expand.
Recent momentum (last 12 months)
Pipeline (CRM snapshot)
- Open pipeline: €3.3M TCV across 260 opportunities (all stages, both revenue layers)
- Forecast-weighted pipeline: €1.0M
- New business 2026: €599K TCV (€366K won + €233K in active pipeline)
- ~190 early-stage opportunities carry no amount yet
- 2025 bookings (TCV signed): ~€903K
- Live CRM data available on request